Annual Report

The report describes a year of strong growth, with sales turnover reaching BDT 7.89 billion, up 21.56%. The company introduced 40 new generics in 55 dosage forms and strengths and registered 48 products in eight countries. It also received EU GMP accreditation for its oral solid dosage and ophthalmic facilities.